Table 1 Comparison of general data and clinical manifestations between the two groups
Item | Classify | PB-group | Non-PB-group | χ2/Ζ | p |
|---|---|---|---|---|---|
Number | 66 | 148 | |||
gender | male | 34(35.05%) | 63(64.95%) | 1.475 | 0.225 |
female | 32(27.35%) | 85(72.65%) | |||
age[M(Q25,Q75), year] | 7(5 ~ 8) | 6(4 ~ 8) | -1.894 | 0.058 | |
Length of stay[M(Q25,Q75), day] | 9(7 ~ 11) | 8(7 ~ 10) | -2.568 | 0.01 | |
Febrile days[M(P25,P75), day] | 9(7 ~ 10) | 8(6 ~ 9) | -3.45 | <0.001 | |
Cough days[M(P25,P75), day] | 11(9 ~ 14.25) | 11(9 ~ 13.75) | -0.782 | 0.434 | |
Methylprednisolone days[M(P25,P75), day] | 7(5 ~ 9) | 5.5(3 ~ 7) | -3.757 | <0.001 | |
Drug resistance | yes | 38(46.34%) | 44(53.66%) | 14.975 | <0.001 |
no | 28(26.92%) | 104(78.79%) | |||
Oxygen therapy | yes | 11(32.35%) | 23(67.65%) | 0.043 | 0.835 |
no | 55(30.56%) | 125(69.44%) | |||
Lung consolidation | yes | 52(33.33%) | 104(66.67%) | 1.676 | 0.195 |
no | 14(24.14%) | 4475.86%) | |||
Pleural effusion | yes | 23(63.89%) | 13(36.11%) | 22.162 | <0.001 |
no | 43(24.16%) | 135(75.84%) |